TB Alliance manages the largest pipeline of new TB drugs in history and has advanced multiple products to market. We prioritize the development of treatments with the greatest potential impact, working independently and with partners to advance promising compounds and regimens. At times, this includes providing compounds for inclusion in partner-led trials.
Explore our interactive portfolio to track the progress of TB drugs and regimens in development. Toggle between views to see how we are also working with partners to investigate the potential of select compounds to treat other neglected and biologically-adjacent diseases, including leprosy and nontuberculous mycobacterial infections.